Melanie Gloria sold $90k of IMVT
Chief Operating Officer at Immunovant, Inc.. 3,238 shares at an average of $27.85, traded Feb 25, 2026, filed Feb 27, 2026.
Score components
- +20RoleCOO
- +9Trade size$90k at market
- 0Share of holdings soldSold 1.9% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001764013-26-000013, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 25, 2026 | SOpen-market sale Common Stock | -1,437 | $26.98 | $39k | 172,074 | Feb 27, 2026 |
| Feb 25, 2026 | SOpen-market sale Common Stock | -859 | $28.16 | $24k | 171,215 | Feb 27, 2026 |
| Feb 25, 2026 | SOpen-market sale Common Stock | -942 | $28.90 | $27k | 170,273 | Feb 27, 2026 |
Related signals
Other insiders at Immunovant, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | Immunovant, Inc. | Melanie Gloria Chief Operating Officer | $72k 2,241 shares | -1% | |
| 40Moderate | Immunovant, Inc. | Jay S Stout Chief Technology Officer | $122k 3,809 shares | -2% | |
| 36Weak | Immunovant, Inc. | Christopher Van Tuyl Chief Legal Officer | $43k 1,327 shares | -1% | |
| 35Weak | Immunovant, Inc. | Eric Venker Chief Executive Officer | $120k 3,506 shares | -1% | |
| 40Moderate | Immunovant, Inc. | Christopher Van Tuyl Chief Legal Officer | $103k 2,846 shares | -2% | |
| 23Weak | IMVTsell Immunovant, Inc. | Christopher Van Tuyl Chief Legal Officer | $72k 2,877 shares | -2% | |
| 22Weak | IMVTsell Immunovant, Inc. | Jay S Stout Chief Technology Officer | $51k 1,977 shares | -1% | |
| 20Weak | IMVTsell Immunovant, Inc. | Jay S Stout Chief Technology Officer | $32k 1,203 shares | -1% | |
| 29Weak | IMVTsell Immunovant, Inc. | Christopher Van Tuyl Chief Legal Officer | $291k 10,813 shares | -7% | |
| 43Moderate | IMVTbuy Immunovant, Inc. | Roivant Sciences Ltd. director, owner | $350M 16,666,666 shares | +17% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.